Status:

COMPLETED

A Feasibility Study of Oral Adjuvant Chemotherapy With S-1

Lead Sponsor:

Tomoshi Tsuchiya

Conditions:

Non-small Cell Lung Cancer

Eligibility:

All Genders

20-79 years

Phase:

PHASE2

Brief Summary

The investigators confirm the feasibility of 1-year administration of oral fluoropyrimidine S-1 as an adjuvant chemotherapy for the patient who received complete resection of non-small cell lung cance...

Detailed Description

Chemotherapy comprised eight courses (4-week administration, 2-week withdrawal) of S-1 (FT, gineracil, oteracil potassium; Taiho Pharmaceutical, Tokyo, Japan) at 80-120 mg/body/day according to body s...

Eligibility Criteria

Inclusion

  • NSCLC with histological proof.
  • Pathological stage IB, II, or IIIA NSCLC (fifth edition of UICC/AJCC 1997) after complete resection.
  • No prior treatment except for surgery.
  • Sufficient oral intake.
  • Performance status (PS) 0 or 1.
  • Patients also had to have adequate organ function (3500 \<leukocytes \< 12,000/mm3; thrombocytes, \>100,000/mm3; total bilirubin,\<1.5 mg/dl; AST and ALT, less than twice the normal limits at each institution; BUN, \<25 mg/dl; creatinine, less than the normal limits at each institution; and creatinine clearance (Ccr))

Exclusion

  • History of drug hypersensitivity.
  • Contraindication of oral S-1 administration (refer appended paper).
  • Serious surgical or non-surgical complications
  • Active secondary cancer.
  • Watery diarrhea.
  • Pregnant or lactating women.
  • Male who has intention to make pregnant
  • Patient to whom primary doctor judged inadequate to register.

Key Trial Info

Start Date :

June 1 2005

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

March 1 2012

Estimated Enrollment :

55 Patients enrolled

Trial Details

Trial ID

NCT01459185

Start Date

June 1 2005

End Date

March 1 2012

Last Update

September 25 2014

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Division of Surgical Oncology, Nagasaki University Graduate School of BIomedical Sciences

Nagasaki, Nagasaki, Japan, 852-8501